ReviewProfiles of drug substances, excipients, and related methodology2013
Melatonin: comprehensive profile.
Review in Profiles of drug substances, excipients, and related methodology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03848533 (Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain.Pharmaceutics · 2023Review
- Molecular Mechanisms of Melatonin-Mediated Cell Protection and Signaling in Health and Disease.Pharmaceutics · 2021Review
- Melatonin in Wine and Beer: Beneficial Effects.Molecules (Basel, Switzerland) · 2021Review
- The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinion.Pharmacology research & perspectives · 2020Review
- Melatonin: new insights on its therapeutic properties in diabetic complications.Diabetology & metabolic syndrome · 2020Review
- Dissolution of Intact, Divided and Crushed Circadin Tablets: Prolonged vs. Immediate Release of Melatonin.Pharmaceutics · 2016Article
- When indomethacin fails: additional treatment options for "indomethacin responsive headaches".Current pain and headache reports · 2015Review
- Clinical pharmacology of melatonin in the treatment of tinnitus: a review.European journal of clinical pharmacology · 2015Review
- Analgesic, anxiolytic and anaesthetic effects of melatonin: new potential uses in pediatrics.International journal of molecular sciences · 2015Review
- Influences of the circadian clock on neuronal susceptibility to excitotoxicity.Frontiers in physiology · 2013Review
- Melatonin protects against diazinon-induced neurobehavioral changes in rats.Neurochemical research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This chapter includes the aspects of melatonin. The drug is synthesized in the pineal gland starting from tryptophane or synthetically by using indole as starting material. Melatonin has been used as an adjunct to interleukin-2 therapy for malignant neoplasms, as contraceptive, in the management of various forms of insomnia, to alleviate jet lag following long flights, and finally as free radical scavenger and hence as an antioxidant and an anti-inflammatory. The chapter discusses the drug metabolism and pharmacokinetics and presents various method of analysis of this drug such as biological analysis, spectroscopic analysis, and chromatographic techniques of separation. It also discusses its physical properties such as solubility characteristics, X-ray powder diffraction pattern, and thermal methods of analysis. The chapter is concluded with a discussion on its biological properties such as activity, toxicity, and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.